Sunshine Biopharma Inc.
SBFM· Nasdaq
SBFMSunshine Biopharma Inc.
Filed Nov 5, 2024 · 10-Q · 36 days after period end · 0001683168-24-007622
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $8.44M | $5.96M | $132.81K | $50.38K |
| Net Income | -$1.20M | -$651.48K | -$1.46M | -$4.04M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sunshine Biopharma Inc. · CIK 1402328 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 5, 2024 · 36 d after period end
